Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.38 |
| ▸ | DRD3 | P35462 | 10/20 | 0.38 |
| ▸ | DRD4 | P21917 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217847 | 0.91 | F2 (0.41) | DRD2DRD3DRD4HRH3 | |
| SCHEMBL5218872 | 0.89 | HRH3 (0.36) | DRD2DRD3DRD4HRH3 | |
| SCHEMBL5217714 | 0.85 | HRH3 (0.37) | DRD2DRD3DRD4HRH3MEN1 | |
| SCHEMBL5217173 | 0.84 | DRD2 (0.55) | DRD2DRD3DRD4HRH3 | |
| SCHEMBL6796054 | 0.84 | DRD2 (0.55) | DRD2DRD3DRD4HRH3 | |
| SCHEMBL5222458 | 0.82 | MAPT (0.37) | DRD2DRD3DRD4HRH3 | |
| SCHEMBL5219946 | 0.79 | DRD2 (0.55) | DRD2DRD3DRD4MEN1ALDH1A1 | |
| SCHEMBL14341127 | 0.78 | DRD3 (0.41) | DRD2DRD3DRD4HRH3MEN1 | |
| SCHEMBL5216026 | 0.76 | ALDH1A1 (0.44) | DRD2DRD3DRD4MEN1ALDH1A1 | |
| SCHEMBL5217360 | 0.75 | DRD2 (0.57) | DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453806-B1 | AMINOTETRALIN DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONIST | HOFFMANN LA ROCHE (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-6806278-B2 | SUCH AS (4-((6,7-DIMETHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINO) -PIPERIDIN-1-YL)(4-METHYL-PIPERAZIN-1-YL)-METHANONE; SMOOTH MUSCLE AND RESPIRATORY DISORDERS | SYNTEX (U.S.A.) LLC | 2004-10-19 | — | — | US | disclosed |
| EP-1453806-A1 | AMINOTETRALIN DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONIST | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| US-20040092604-A1 | Amino-tetralin derivatives as muscarinic receptor antagonists | MADERA ANN MARIE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635658-B2 | Amino tetralin piperidiene derivatives; smooth muscle disorders comprising diseases of genitourinary or gastro-intestinal tract | SYNTEX (U.S.A.) LLC | 2003-10-21 | — | — | US | disclosed |
| US-20030171362-A1 | AMINO-TETRALIN DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | SYNTEX (USA) LLC | 2003-09-11 | — | — | US | disclosed |
| WO-2003048125-A1 | AMINOTETRALIN DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171362-A1 | AMINO-TETRALIN DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | DRD2 126/4885DRD3 133/4885DRD4 197/4885 |
| US-20040092604-A1 | Amino-tetralin derivatives as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | DRD2 126/4885DRD3 133/4885DRD4 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.